Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27766119 | 0.79 | HPGD (0.31) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL6259547 | 0.78 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL28052835 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| Iodide SCHEMBL6303658 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| Iodide SCHEMBL6303659 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL18986896 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL7363330 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL260096 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL27823990 | 0.76 | — | — | |
| SCHEMBL24786623 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-115925649-A | Method for preparing 4-methylthiazole-5-formaldehyde by continuous flow | 深圳市茵诺圣生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| CN-114099503-B | Application of compound as CYP2E1 inhibitor | 苏州灵希生物科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| CN-116059362-A | Application of CYP2E1 inhibitor in preparation of medicines for treating or preventing inflammation-related diseases | 上海灵希生物科技发展有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115925649-A | Method for preparing 4-methylthiazole-5-formaldehyde by continuous flow | 深圳市茵诺圣生物科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115925649-A | Method for preparing 4-methylthiazole-5-formaldehyde by continuous flow | 深圳市茵诺圣生物科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| CN-102712620-A | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| WO-2012004722-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-01-12 | — | — | WO | disclosed |
| CN-102234253-A | Method for preparing febuxostat intermediate | CHONGQING LUMMY PHARMACEUTICAL | 2011-11-09 | — | — | CN | disclosed |
| CN-102186824-A | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL | 2011-09-14 | — | — | CN | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| EP-0539372-A1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1991011448-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1991-08-08 | — | — | WO | disclosed |
| US-4665066-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885KMT2A 2697/4885MEN1 2644/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885KMT2A 2697/4885MEN1 2644/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | ALDH1A1 978/4885KMT2A 2697/4885MEN1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.